Trial Information
Leptomeningeal Metastases (LM) is sometimes referred to as leptomeningeal cancer, leptomeningeal disease, neoplastic meningitis, or meningeal carcinomatosis. This rare but serious condition happens when cancer cells spread to the membranes surrounding the brain and spinal cord. Leptomeningeal Metastases is most commonly found in patients with melanoma, breast, lung, or gastrointestinal cancer. Unfortunately, there are no FDA approved treatments specifically for Leptomeningeal Metastases.
Plus Therapeutics is developing a new targeted radiation therapy, Rhenium (186Re) Obisbemeda, for central nervous system cancers such as Leptomeningeal Metastases. In the U.S. ReSPECT-LM clinical trial, doctors will give Leptomeningeal Metastases patients a single dose of Rhenium (186Re) Obisbemeda through a small catheter placed under the patient’s scalp. This drug will be administered in less than 5 minutes in a hospital setting and the patient will go home the same day.
The ReSPECT-LM clinical trial is funded, in part, by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas, the second largest public funding source for cancer research in the world.
NATIONAL TRIAL REFERENCE NUMBER
NCT05034497
When speaking with your physician, please have the national trial reference number available.
Patients Treated to Date
Single Group
- All patients who enroll in the trial will receive medication while on the study.
- All patients will receive a single dose of Rhenium (186Re) Obisbemeda.
Phase 1
- A Phase 1 study is the first step in testing a new treatment in humans. A phase I clinical trial tests the safety, side effects, best dose, and timing of a new treatment. It may also test how the treatment affects the body. The dose is usually increased a little at a time in order to find the highest dose that does not cause harmful side effects. Phase I clinical trials usually include only a small number of patients who have not been helped by other treatments.
Progress
- Actual Study Start: December 6, 2021
- Estimated Primary Completion: December 21, 2025 (the date that the last participant in a clinical study was examined or received an intervention and that data for the primary outcome measure were collected)
- Estimated Study Completion: June 30, 2026 (the date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events, that is, the last participant's last visit).
Plus Therapeutics is evaluating rhenium (186Re) obisbemeda, a novel radiotherapy for patients with Leptomeningeal Metastases in a Phase 1 clinical trial.
Watch now to learn more.
Patient Eligibility
Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. Patient reimbursement of up to $599 for time and travel is available.
Age Range
Adults, 18 years and older
Condition
Leptomeningeal Metastases from any solid tumor cancers (i.e. breast, lung, melanoma, gastrointestinal)
Prior Treatment
No prior whole brain or spinal cord radiation therapy
Informed Consent
Able to understand the study purposes and risks
Gender
All; Women have negative pregnancy test at screening; Subjects must use effective contraception during study
Additional eligibility criteria may be found on ClinicalTrials.gov
Principal Investigators
There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.
Andrew Brenner, M.D., Ph.D.
UT Health San Antonio, Mays Cancer Center
Texas
Michael Youssef, M.D.
UT Southwestern Medical Center
Texas
Priya Kumthekar, M.D.
Northwestern Memorial Hospital
Illinois
Michael Schulder, M.D.
North Shore University Hospital
New York
Shirley Ong, M.D.
The Ohio State University Cancer Center
Columbus, Ohio
Randy S. D’Amico, M.D.
Lenox Hill Hospital
New York, New York
Trial Locations
Please visit this website regularly for updates as new locations are added.
UT Health Science Center
San Antonio
North Shore University Hospital
New York
UT Southwestern Medical Center
Dallas
Ohio State University
Columbus
Northwestern Memorial Hospital
Chicago
Lenox Hill Hospital
New York
What Can You Do Next?
Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.
Discuss With Your Physician
Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your physician first.
Print, save, or email this page to your physician to discuss at your next visit.
Be sure to have National Trial Reference Number NCT05034497 available.
Contact A Trial Coordinator
A trial coordinator is a specialized researcher who supports the management and coordination of clinical research studies. If you are interested in participating in a clinical trial, you may call a trial coordinator directly at one of the trial locations below.
UT Health Science Center
San Antonio
Leticia Velten
210-450-1921
velten@uthscsa.edu
North Shore University Hospital
Manhasset
Betsy Moclair
516-253-7753
bmoclair@northwell.edu
UT Southwestern Medical Center
Dallas
Tammy Rickfels
469-852-0719 or 214-645-2148
tammy.ricklefs@utsouthwestern.edu
Ohio State University Cancer Center
Columbus
Jake Lanning
614-685-2435
jake.lanning@osumc.edu
Northwestern Memorial Hospital
Chicago
Laura Sharp
312-926-5115
laura.sharp@northwestern.edu
Lenox Hill Hospital
New York
Tamika Wong
212-434-4836
twong4@northwell.edu
Contact Us
Request More Information
News
August 13, 2024
August 12, 2024
July 25, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
July 2, 2024
June 7, 2024
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
May 9, 2024
April 22, 2024
April 9, 2024
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
March 27, 2024
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
March 25, 2024
March 11, 2024
December 12, 2023
November 29, 2023
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
- Presentation titled “Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors”
November 3, 2023
October 10, 2023
- Cohort 4 of the ReSPECT-LM Phase 1 dose escalation trial is the first of 4 planned cohorts in Part B; the Company anticipates moving into Cohort 5 following standard safety review
September 11, 2023
September 5, 2023
Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastases
- Plus Therapeutics announced treatment of the first patient in Part B (Cohort 4) of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases (LM) from solid tumors.
August 11, 2023
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
- Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases. FDA approves continuation to Phase 1 Part B of the ReSPECT-LM clinical trial.
Publications
Posters
Presentations
Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM), SNO/ASCO CNS Metastases Conference Oral Presentation, August 8, 2024
Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases, SNO/ASCO CNS Metastases Independent Symposium, August 8, 2024
Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials, Gordon Research Conference, July 8, 2024
Phase 1A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM), Cancer Prevention & Research Institute of Texas (CPRIT) Innovations Conference, October 3, 2023
KOL Roundtable on Leptomeningeal Metastases: An Obvious Disease Target for Radiotherapeutic Intervention, SNO/ASCO CNS Cancer Conference, August 11, 2023
Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial, EANM Congress, October 19, 2022
Resources
Note: all external links
- American Brain Tumor Association
- American Cancer Society
- Brain Tumor Network
- Dictionary of Cancer Terms
- End Brain Cancer Initiative
- MedlinePlus (NIH)
- National Brain Tumor Society
- National Cancer Institute
- National Comprehensive Cancer Network
- Support Groups Listing
- The Brain Tumour Charity
- Trial Connect
- VirtualTrials.com
- Voices Against Brain Cancer
Updates
SNO/ASCO Symposium
You're Invited to our symposium "Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases," presented at the SNO/ASCO CNS conference in Denver. More information & RSVP: https://bit.ly/4bM777e "Emerging Novel Diagnostic and Therapeutic...
2024 SNO/ASCO Curtain Raiser
UPCOMING PRESENTATIONS: Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference and scheduled to present new data, highlighting progress in its therapeutics and diagnostics programs for Leptomeningeal Metastases Read the full details...
Radiotherapeutics Q&A
"Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach to treating many types of cancer. In RPT, radiation is systemically or locally delivered. To learn more about emerging developments, Digital Journal spoke with Marc Hedrick, MD...
Gordon Research Conference
Join us at the Gordon Research Conference: Radionuclide Theranostics for the Management of Cancer, being held July 7-12 in Newry, Maine, as Plus Therapeutics takes the stage. Presentation by Melissa Moore, Ph.D. Press Release: https://bit.ly/PSTV_PR...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
